All news

Spineway, specialized in the design of innovative surgical implants and instruments for the treatment of severe disorders of the spine, continues its international development with the organization of a workshop in Thailand on the use of its products, and the signature of a distribution agreement in the US state of Ohio.

Spineway, specialized in innovative implants for the treatment of severe disorders of the spinal column (spine), announces that it has entered exclusive negotiations with a view to the acquisition of 100% of the capital of a European start-up specialized in the design, manufacture and sale of implants and instruments for spinal surgery.

The Combined General Meeting of Spineway’s shareholders was held upon first notice of meeting on Monday, 8 March 2020, behind closed doors, at the Company’s registered office. The number of shares held by the shareholders represented amounted to 3 232 993 768 shares, i.e., a turnout of 25.79%.

Spineway announces the signature of a partnership with the Italian company Tsunami Medical, pioneer in innovative 3D-printed solutions, for the sale of Twin Peaks interbody cages produced with 3D printers.

Spineway, specialized in the treatment of severe disorders of the spine, announces the first surgery in Thailand with Mont Blanc 3D+ instrumentation as well as the signature of an exclusive distribution agreement for the marketing of its products in Malaysia.

2019 was a particularly active year for the SPINEWAY group as it redeployed its activities in previously covered areas, completely reorganized its teams and renewed half its Executive Committee at the end of 2019. Spineway also strengthened its financial position thanks to a financing agreement with Negma Group1 in order to ensure organic growth and finance new development projects. The Group thus generated total revenue of €5 015K for 2019.

Spineway, specialized in innovative implants for the treatment of severe disorders of the spinal column (spine), announces its choice of TUV Rheinland as the notified body for the certification of its implant and instrument product lines. With the European regulations governing medical devices constantly changing and ever more stringent, Spineway thus ensures that it will be able to provide high-quality products consistently.

The Extraordinary and Ordinary General Meeting of Spineway’s shareholders that was held behind closed doors on 26 May 2020, at 2 p.m. at the Group’s registered office located at 7 allée Moulin Berger, 69130 Ecully, adopted all the resolutions submitted by over 90% except for resolution no. 10, which was dismissed unanimously at the Board of Directors’ recommendation. During this Meeting, the decision was approved to decrease the company’s share capital by absorbing losses and decreasing the par value of the shares.

Spineway’s Board of Directors, at a meeting held on 25 January 2021 chaired by Stéphane Le Roux, closed the 2020 annual accounts.